Daily Archives: October 14, 2020
Genomic evidence for reinfection with SARS-CoV-2: A case study
14 Oct, 2020 | 09:39h | UTCGenomic evidence for reinfection with SARS-CoV-2: a case study – The Lancet Infectious Diseases
Commentaries: First Case Of COVID-19 Reinfection In The US Confirmed; Exposure to Virus May Not Guarantee Protective Immunity, Says New Lancet Study – Health Policy Watch AND What reinfections mean for COVID-19 – The Lancet Infectious Diseases AND You can get reinfected with Covid-19 but still have immunity. Let’s explain. – Vox AND A 25-Year-Old Nevada Man Got COVID-19 Twice. Here’s What We Know—and Don’t Know—About Reinfection – TIME
Related: Dutch woman dies after catching Covid-19 twice, the first reported reinfection death – CNN
Updated NIH COVID-19 Treatment Guidelines
14 Oct, 2020 | 09:41h | UTCCoronavirus Disease 2019 (COVID-19) Treatment Guidelines – National Institutes of Health
See also: What’s New in the Guidelines
COVID-19 in New Zealand and the impact of the national response: A descriptive epidemiological study
14 Oct, 2020 | 09:38h | UTCCommentary: Lessons from New Zealand’s COVID-19 outbreak response – The Global Health
Commentary on Twitter
How New Zealand crushed covid: rapid, aggressive use of masks, distancing, testing, isolation, travel ban. Hard work.
Transmission chains notable (wedding, school clusters)https://t.co/FMCgQOsVYJhttps://t.co/svRZyjvOf2 @AlxsRobert @TheLancetPH ???? pic.twitter.com/WqxAySjqJy— Eric Topol (@EricTopol) October 14, 2020
COVID-19 and cancer: Current challenges and perspectives
14 Oct, 2020 | 09:35h | UTCCOVID-19 and Cancer: Current Challenges and Perspectives – Cancer Cell
Johnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant
14 Oct, 2020 | 09:31h | UTCJohnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant – STAT
News Release: Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials
Commentaries: Johnson & Johnson ‘Pauses’ COVID-19 Vaccine Trial Due To Unexplained Illness In Participant; Eli Lilly Reportedly Suspending Trial Of Antibody Treatment – Health Policy Watch AND Johnson & Johnson pauses Covid-19 vaccine trial after ‘unexplained illness’ – CNN
Non-respiratory presentations of COVID-19, a clinical review
14 Oct, 2020 | 09:33h | UTC
Monoclonal antibody trial halted for safety concern
14 Oct, 2020 | 09:30h | UTCMonoclonal Antibody Trial Halted for Safety Concern – Brief19
Covid-19: how to prioritize worse-off populations in allocating safe and effective vaccines
14 Oct, 2020 | 09:25h | UTC
COVID-19 will probably become endemic – here’s what that means
14 Oct, 2020 | 09:27h | UTCCOVID-19 will probably become endemic – here’s what that means – The Conversation
[Abstract Only] Randomized trials: Efficacy and safety of a plant-derived influenza vaccine in adults
14 Oct, 2020 | 09:23h | UTCEfficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
NEW—First large-scale studies of plant-derived, quadrivalent, virus-like particle influenza vaccine show substantial protection against respiratory illness & influenza-like illness caused by influenza viruses in adults: two randomised phase 3 trials https://t.co/oQbs2uJTXY pic.twitter.com/C6b6Qi6qZ7
— The Lancet (@TheLancet) October 13, 2020
Case report: Sudden irreversible hearing loss post COVID-19
14 Oct, 2020 | 09:24h | UTCSudden irreversible hearing loss post COVID-19 – BMJ Case Reports
Commentaries: Coronavirus: Patient has sudden permanent hearing loss – BBC AND First reported UK case of sudden permanent hearing loss linked to COVID-19 – BMJ
Commentary on Twitter
Sudden hearing loss after #COVID19.
Report of 1st UK case and review of the other 4 published reports (must be *extremely rare*)https://t.co/wCkrgHcwKH pic.twitter.com/onQxxYiImb— Eric Topol (@EricTopol) October 13, 2020
Meta-analysis: Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension
14 Oct, 2020 | 09:20h | UTC
Commentary on Twitter
Which lifestyle intervention works best for hypertension? #Bayesian meta-analysis suggests the #DASH diet https://t.co/1CgLVwN4LB #AHAJournals @tinauchojo pic.twitter.com/wzJ87OPT0m
— JAHA (@JAHA_AHA) October 5, 2020
Meta-analysis: Overall and cause-specific mortality in randomized clinical trials comparing percutaneous interventions with coronary bypass surgery
14 Oct, 2020 | 09:16h | UTCOverall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis – JAMA Internal Medicine (free for a limited period)
Commentary on Twitter
In an analysis of 23 randomized trials comparing CABG and PCI, PCI was associated with higher rates of cardiac, non-cardiac, and all-cause mortality. All-cause mortality should be used as endpoint in revascularization trials https://t.co/DBSvVkr3EK
— JAMA Internal Medicine (@JAMAInternalMed) October 12, 2020
Meta-analysis: Association of receipt of palliative care interventions with health care use, quality of life, and symptom burden among adults with chronic noncancer illness
14 Oct, 2020 | 09:18h | UTCEditorial: Palliative Care for Patients With Noncancer Illnesses
Commentary on Twitter
In this meta-analysis of RCTs of patients with primarily noncancer illness (mostly heart failure) palliative care was associated w less acute health care use & lower symptom burden, with no difference in quality of life https://t.co/ZtH6w48vz4 @kieranlquinn
— JAMA (@JAMA_current) October 13, 2020